» Articles » PMID: 26495987

A Trial of Lifestyle Modification on Cardiopulmonary, Inflammatory, and Metabolic Effects Among Obese with Chronic Kidney Disease

Overview
Journal Am J Nephrol
Publisher Karger
Specialty Nephrology
Date 2015 Oct 27
PMID 26495987
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The feasibility and benefits of lifestyle intervention in chronic kidney disease (CKD) patients who are obese has not been well studied. We examined the early effects of an exercise plus weight loss intervention on body composition, exercise capacity, metabolic parameters and kidney function in obese subjects with CKD.

Methods: Nine subjects (median age 57 years, body mass index (BMI) 43.9) underwent a lifestyle intervention program that included supervised aerobic exercise (i.e. ∼85% maximum heart rate) and dietary counseling (500 kcal reduction in daily caloric intake). Body composition (iDXA), exercise capacity (maximal oxygen consumption), quality of life, insulin resistance (Matsuda index), inflammation (high sensitivity C-reactive protein), adipokines (leptin and total adiponectin) and kidney function (iothalamate glomerular filtration rate) were measured at baseline and after 12 weeks of the intervention. Changes in parameters were compared using the Wilcoxon signed-rank test.

Results: After 12 weeks of intervention, there was a significant decrease in BMI and fat mass (median -4.9 kg (25th-75th percentile -5.9 to -3.0)). There was a significant increase in exercise capacity (3.7 ml/kg/min (3.0-4.7)), along with improvements in insulin sensitivity (0.55 (0.43-1.2)), total adiponectin (780.9 μg/ml (262.1-1,497.1)) and leptin (-5.1 ng/ml (-14.5 to -3.3)). There were improvements in biomarkers of kidney disease very quality of life measures, but kidney function remained unchanged.

Conclusion: Lifestyle modification is feasible in obese patients with CKD and produces weight loss that is related to improvements in exercise capacity, insulin resistance and adipokines. Whether lifestyle-induced weight loss and fitness can be sustained and whether it will mediate improvements in kidney function over time merits further investigation.

Citing Articles

Exercise and chronic kidney disease: potential mechanisms underlying the physiological benefits.

Bishop N, Burton J, Graham-Brown M, Stensel D, Viana J, Watson E Nat Rev Nephrol. 2023; 19(4):244-256.

PMID: 36650232 DOI: 10.1038/s41581-022-00675-9.


Exercise and Reduced Nicotine Content Cigarettes in Adult Female Smokers: A Pilot Trial.

Li C, Yao N, Miller S, Macpherson C, Hassinger T, Love K Int J Environ Res Public Health. 2022; 19(11).

PMID: 35682232 PMC: 9180864. DOI: 10.3390/ijerph19116647.


Chronic Renal Failure and Cardiovascular Disease: A Comprehensive Appraisal.

Skalsky K, Shiyovich A, Steinmetz T, Kornowski R J Clin Med. 2022; 11(5).

PMID: 35268426 PMC: 8911484. DOI: 10.3390/jcm11051335.


Exercise plus caloric restriction lowers soluble RAGE in adults with chronic kidney disease.

Malin S, Navaneethan S, Fealy C, Scelsi A, Huang H, Rocco M Obes Sci Pract. 2020; 6(3):307-312.

PMID: 32523720 PMC: 7278900. DOI: 10.1002/osp4.408.


Leptin, cardiovascular diseases and type 2 diabetes mellitus.

Katsiki N, Mikhailidis D, Banach M Acta Pharmacol Sin. 2018; 39(7):1176-1188.

PMID: 29877321 PMC: 6289384. DOI: 10.1038/aps.2018.40.


References
1.
Kelly K, Navaneethan S, Solomon T, Haus J, Cook M, Barkoukis H . Lifestyle-induced decrease in fat mass improves adiponectin secretion in obese adults. Med Sci Sports Exerc. 2014; 46(5):920-6. PMC: 3991752. DOI: 10.1249/MSS.0000000000000200. View

2.
Inker L, Astor B, Fox C, Isakova T, Lash J, Peralta C . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-35. DOI: 10.1053/j.ajkd.2014.01.416. View

3.
Xu H, Huang X, Arnlov J, Cederholm T, Stenvinkel P, Lindholm B . Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4. Clin J Am Soc Nephrol. 2014; 9(4):690-7. PMC: 3974352. DOI: 10.2215/CJN.05230513. View

4.
Navaneethan S, Schold J, Kirwan J, Arrigain S, Jolly S, Poggio E . Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol. 2013; 8(6):945-52. PMC: 3675852. DOI: 10.2215/CJN.09870912. View

5.
Navaneethan S, Kirwan J, Arrigain S, Schreiber M, Sehgal A, Schold J . Overweight, obesity and intentional weight loss in chronic kidney disease: NHANES 1999-2006. Int J Obes (Lond). 2012; 36(12):1585-90. PMC: 3342418. DOI: 10.1038/ijo.2012.7. View